Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 22;27(10):839–848. doi: 10.1093/oncolo/oyac094

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Genomic landscape of non-small cell lung cancer brain metastases (NSCLC-BM). (A) Co-mutation plot of the top 15 genes with genomic alterations (GAs) in NSCLC-BM. In the NSCLC-BM cohort (n = 3035), the top 15 most altered genes were TP53 (77.0%, 2337), KRAS (37.7%, 1143), CDKN2A (32.9%, 998), STK11 (22.2%, 675), CDKN2B (21.0%, 637), EGFR (14.2%, 432), NKX2-1 (11.6%, 353), RB1 (11.4%, 347), MYC (10.6%, 323), KEAP1 (10.3%, 313), NFKBIA (9.5%, 288), SMARCA4 (9.3%, 283), NF1 (8.8%, 268), RICTOR (8.4%, 256), and PIK3CA (8.1%, 245). (B) Longtail plot of the top 15 genes with GAs between the NSCLC-BM and primary NSCLC (pNSCLC). NSCLC-BMs that were significantly enriched for GAs when compared to pNSCLC in TP53, KRAS, CDKN2A, STK11, CDKN2B, NKX2-1, RB1, MYC, KEAP1, NFKBIA, SMARCA4, RICTOR, and decreased for prevalence of PIK3CA. Significant differences are designated by horizontal black lines above each comparison group.